Cognition Therapeutics (CGTX)
(Delayed Data from NSDQ)
$0.58 USD
-0.03 (-4.89%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.58 0.00 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
CGTX 0.58 -0.03(-4.89%)
Will CGTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CGTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CGTX
Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?
CGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGTX
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
Cognition Therapeutics Shares Investor Presentation Update
Cognition Therapeutics announces results from the SEQUEL study of CT1812
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer?s Disease
Cognition Therapeutics, Inc. (CGTX) Q1 2024 Earnings Call Transcript